News

The Charcot-Marie-Tooth Association today welcomed Craig Zeltsar, principal and co-founder of NNE Marketing, LLC, to its Board of Directors.

A team led by Dr. Stephan Züchner at the University of Miami has discovered a new type of Charcot-Marie-Tooth (CMT) disease that may be treatable with drugs already approved for other diseases.

The CMTA Board of Directors approved a $265,000 research project for CMT2E that aims to advance CMT2E gene therapy by demonstrating positive results for axonal forms of CMT affecting motor neurons.

In a world turned upside down, The CMTA Report continues to bring you help for today and hope for tomorrow. In this issue you’ll find helpful stories on tendon transfers, HNPP and nerve conduction studies, as well as hopeful news ...

The CMTA Board of Directors approved a new research project aimed at developing biomarkers for CMT1B to aid in the collection of natural history data critical to clinical trials.